Research progress of pharmacotherapy on delayed cerebral vasospasm after subarachnoid hemorrhage

Abstract

Abstract: Delayed cerebral vasospasm (DCVS) is an important incapacitating or lethal cause after sub-arachnoid hemorrhage (SAH) , but the patho-physiolog-ical process was vague .The effective drugs of treating DCVS are particularly important including ion channel blockers or openers, endothelin synthetic inhibitor or receptor antagonist, anti-inflammatory agents, antioxi-dants, fibrinolytic agents, traditional Chinese herbs, etc. The article reviews the research progress in the preclin-ical and clinical pharmacotherapy on DCVS after SAH, and explores the applications and effects and debates about these therapeutic drugs at present .

Key words: subarachnoid hemorrhage, delayed cerebral vasospasm, pharmacotherapy

CLC Number:

R453
R743.35

XIONG Fang-ling, GAO Yi-lu. Research progress of pharmacotherapy on delayed cerebral vasospasm after subarachnoid hemorrhage[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 955-960.

References

[1] Azizov VA, Muradova SR.Atrial Natriuretic Peptide and cardiovas Cular system[J] .Anadolu kardiyol Derg, 2001, 1(4):297-300.
[2] Dorhout Mees SM, Rinkel GJE, Feigin VL, et al.Calci-um antagonists for aneurysmal subarachnoid hemorrhage[J] .Stroke, 2008, 39(2):514-515.
[3] Kronvall E, Undren P, Romner B, et al.Nimodipine in aneurysmal subarachnoid hemorrhage:a randomized study of intravenous or peroral administration[J] .J Neurosurg, 2009, 110(1):58-63.
[4] Yin YH, Wang F, Pan YH, et al.Effects of dose-re-sponse of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits[J] . Am JMed Sci, 2009, 337(2):123-125.
[5] Kwan AL, Lin CL, Wu CS, et al.Delayed administration of the K+channel activator cromakalim attenuates cerebral vasospasm after experimental subarachnoid hemorrhage[J] .Acta Neurochir(Wien), 2000, 142(2):193-197.
[6] Omeis I, Chen W, Jhanwar-Uniyal M, et al.Prevention of cerebral vasospasm by local delivery of cromakalim with a biodegradable controlled-release system in a ratmodel of subarachnoid hemorrhage[J] .J Neurosurg, 2009, 110(5):1015-1020.
[7] Vatter H, Weidauer S, Konczalla J, et al.Time course in the development of cerebral vasospasm after experimental subarachnoid hemorrhage:clinical and neuroradiological assessment of the rat double hemorrhage model[J] .Neu-rosurg, 2006, 58(6):1190-1197.
[8] Yatsushige H, Yamaguchi-Okada M, Zhou C, et al.Inhi-bition of c-Jun N-terminal kinase pathway attenuates cere-bral vasospasm after experimental subarachnoidhemorrhage through the suppression of apoptosis[J] .Acta Neurochir Suppl, 2008, 104:27-31.
[9] LinCL, Dumont AS, Wu SC, 17β-estradiol inhibitsendo-thelin-1 production and attenuates cerebral vasospasm after experimental subarachnoid hemorrhage[J] .Exp BiolMed, 2006, 231(6):1054-1057.
[10] Shih HC, LinCL, Wu SC, et al.Upregulation of estrogen receptor alpha and mediation of 17beta-estradiol vasopro-tective effects via estrogen receptor alpha in basilar arteries in rats after experimental subarachnoid hemorrhage[J] .J Neurosurg, 2008, 109(1):92-99.
[11] Macdonald RL, Kassell NF, Mayer S, et al.Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1):Ran-domized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial[J] .Stroke, 2008, 39(11):3015-3021.
[12] Pradilla G, Thai QA, Legnani FG, et al.Delayed in-tracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits[J] .Neurosurg, 2004, 55(6):1393-1400.
[13] Sugawara T, Ayer R, Jadhav V, et al.Simvastatin atten-uation of cerebralvasospasm after subarachnoidhemorrhage in rats via increasedphosphorylationof Akt and endothelial nitric oxide synthase[J] .J Neurosci Res, 2008, 86(16): 3635-3643.
[14] Tseng MY, Hutchinson PJ, Czosnyka M, et al.Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage[J] .Stroke, 2007, 38(5):1545-1550.
[15] McGirtMJ, Garces Ambrossi GL, Huang J, et al.Simv-astatin for the prevention of symptomatic cerebral vaso-spasm following aneurysmal subarachnoid hemorrhage:a single-institution prospective cohort study[J] .J Neuro-surg, 2009, 110(5):968-974.
[16] Kramer AH, Gurka MJ, Nathan B, et al.Statin use was not associatedwith less vasospasm or improvedoutcome af-ter subarachnoid hemorrhage[J] .Neurosurg, 2008, 62(2):422-430.
[17] Moskowitz SI, Ahrens C, Provencio JJ, et al.Prehemor-rhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhage[J] .Surg Neurol, 2009, 71(3): 311-318.
[18] Kassell NF, Haley EC, Appersen-Hansen C, et al.Ran-domized double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurismal subarachnoid hemor-rhage:acooperative study in Europe, Australia and ne-wZealand[J] .J Neurosurg, 1996, 84(2):221-228.
[19] Jang YG, Ilodigwe D, Macdonald RL.Metaanalysis of tirilazad mesylate in patientswith aneurysmal subarachnoid hemorrhage[J] .Neurocrit Care, 2009, 10(1):141-147.
[20] Akira M, Hiroki O, Takahiro N, et al.Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage[J] .Neurosurg, 2009, 64(3):423-429.
[21] Hishikawa T, Ono S, Ogawa T, et al.Effects of deferox-amine-activated hypoxia-inducible factor-1 on the brain-stem after subarachnoid hemorrhage in rats[J] .Neuro-surg, 2008, 62(1):232-241.
[22] Katayama Y, Haraoka J, Hirabayashi H, et al.A ran-domized controlled trial of hydrocortisone against hy-ponatremia in patients with aneurismal subarachnoid hem-orrhage[J] .Stroke, 2007, 38(8):2373-2375.
[23] Moro N, Katayama Y, Kojima J, et al.Prophylactic man-agement of excessive natriuresiswith hydrocortisone for ef-ficient hypervolemic therapy after subarachnoid hemorrhage[J] .Stroke, 2003, 34(12):2807-2811.
[24] Wong GK, Poon WS.Risk of high dose hydrocortisone in patients with aneurysmal subarachnoid hemorrhage[J] . Stroke, 2008, 39(1):e12.
[25] Pradilla G, Wang PP, Legnani FG, et al.Prevention of vasospasm by anti -CD 11 CD 18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits[J] .J Neuro-surg, 2004, 101(1):89-92.
[26] Kinouchi H, Ogasawara K, Shimizu H, et al.Prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage by intraoperative cisternal fibrinolysisusing tis-sue-type plasminogen activator combined with continuous cisternal drainage[J] .Neurol Med Chir (Tokyo) , 2004, 44(11):569-577.
[27] Shirao S, Fujisawa H, Kudo A, et al.Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage:Possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway[J] .Ce-rebrovasc Dis, 2008, 26(1):30-37.
[28] Fraticelli AT, Cholley BP, Losser MR, et al.Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage[J] .Stroke, 2008, 39(3):893-898.
[29] 冯加纯, 李玉书, 吴军, 等.实验性犬SAH 后 CVS、脑水肿研究及刺五加的保护作用[J] .中风与神经疾病杂志, 1999, 16(3):133-134.
[30] 马丽, 吴岩, 朱德志, 等.刺五加注射液防治蛛网膜下腔出血继发脑血管痉挛的临床研究[J] .中国老年学杂志, 2003, 11(23):732-733.
[31] Clark WM, Rinker LG, lessov NS, et al.Efficacy of an-tioxidant therapies intransient focal ischemia in mice[J] . Stroke, 2001, 32(4):1000-1004.
[32] Kotil K, Uyar R, Bilge T, et al.Investigationof the dose-dependent antivasospasmic effect of Ginkgo biloba extract (EGb761) in experimental subarachnoid hemorrhage[J] . J Clin Neurosci, 2008, 15(12):1382-1386.
[33] 李永红, 郭科, 资晓宏, 等.舒血宁注射液结合脑脊液置换术治疗蛛网膜下腔出血疗效观察[J] .中国现代医学杂志, 2004, 14(16):83-85.
[34] SunBL, Hu DM, Yuan H, et al.Extract of ginkgo biloba promotes the expression of VEGF following subarachnoid hemorrhage in rats[J] .Int J Neurosci, 2009, 119(7):995-1005.
[35] 张更申, 林成, 张庆俊.胡椒碱对实验性蛛网膜下腔出血后脑血管痉挛作用机理研究[J] .中华神经外科杂志, 2006, 22(6):373-376.